Table 2.
Sensitivity is presented with 95% CIs. Bold text indicates the highest sensitivity among the models at each specificity and test set.
| Specificity | |||
|---|---|---|---|
| 70% | 80% | 90% | |
| TS1 (Clinically Examined PD patients vs. HC) | |||
| dAFSi | 95% (94.0–98.9) | 90% (88.0–93.9) | 51% (23.0–70.9) |
| dBSi | 90% (82.0–100.0) | 69% (40.0-98.9) | 38% (12.0–84.9) |
| dRSi | 92% (83.9–98.9) | 85% (73.0–94.0) | 43% (29.9–68.9) |
| TS2 (Clinically examined de novo PD vs. HC) | |||
| dAFSi | 96% (93.9–98.9) | 96% (93.9–98.9) | 93% (89.0–93.9) |
| dBSi | 92% (83.0–100.0) | 86% (72.0–100.0) | 82% (71.0–94.1) |
| dRSi | 96% (93.8–99.0) | 92% (84.0–98.9) | 87% (77.0–93.9) |
| TS3 (Self-reported PD patients vs. HC) | |||
| dAFSi | 77% (75.0-78.0) | 67% (60.0-72.0) | 40% (20.9-51.0) |
| dBSi | 69% (63.0-79.0) | 54% (31.0-77.1) | 30% (0.05-70.9) |
| dRSi | 77% (70.0-84.0) | 53% (38.0-66.0) | 38% (28.0-50.0) |